AbbVie (ABBV), J&J (JNJ) Announce FDA Approval of IMBRUVICA as First-Line CLL Treatment
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) as a first-line treatment for patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
